Opinion|Videos|September 23, 2024
Long-term Safety of JAK Inhibitors in Atopic Dermatitis
Key Takeaways
- Long-term upadacitinib data reveal sustained efficacy and safety, offering insights beyond short-term studies for atopic dermatitis management.
- Comparisons with other JAK inhibitors highlight differences in long-term outcomes, influencing clinical decision-making.
Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
- What about short vs long-term data with other JAKi?
- How do they impact your use of JAKi for atopic dermatitis?
Advertisement
Related to this article
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
Children aged 2 - 11 with atopic dermatitis saw early, lasting itch and sleep gains with nemolizumab through 1 year in phase 2 data shared at PeDRA 2026.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Advertisement
Advertisement
Trending on HCPLive
1
I-124 Evuzamitide PET/CT Highly Sensitive, Specific in Amyloid Detection
2
CHEST 2026: Day 1 Recap — 5 Headlines to Know
3
VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications
4
Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD
5